Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

Ruxolitinib cream 1.5% shows “breakthrough” results as a treatment for prurigo nodularis, according to a presenter at the ...

in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN). This content was developed independently and is not endorsed by the American ...

Incyte INCY announced positive results from two late-stage studies evaluating the safety and efficacy of its twice-daily ...

More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of starting ...

Shawn Kwatra, MD, FAAD, physician scientist at the University of Maryland Medical System, presented data at the American Academy of Dermatology 2025 annual conference on the rapid efficacy of topical ...

Nemluvio’s approved indications include atopic dermatitis in patients aged 12 years and older and prurigo nodularis in adults. The approvals are supported by two phase 3 clinical trial programs.

The European Commission (EC) has approved Galderma’s Nemluvio (nemolizumab) to treat both atopic dermatitis and prurigo nodularis. The drug has been authorised for use in atopic dermatitis patients ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Galderma’s Nemluvio (nemolizumab) to treat both atopic dermatitis and prurigo nodularis. The UK regulator has specifically ...